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Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC.
Herein, we aimed to investigate the cause of the limited therapeutic effect of selu- 
| INTRODUC TI ON
Head and neck squamous cell carcinoma is the sixth leading cancer by incidence worldwide. 1 Despite high cure rates in early-stage HNSCC with either surgery or radiotherapy, nearly 60% of HNSCC patients still present with locally advanced-stage disease. 2 In HNSCC, multiple mutations or aberrant overactivation of the epidermal growth factor receptor (EGFR)-MEK signaling pathway has been frequently observed. 3, 4 EGFR expression is detected in >90% of HNSCC and frequently triggers the RAS/RAF/MEK/ERK cascade. Clinical and biological evidence has suggested that the ERK pathway may play a pivotal role in tumor progression. ERK hyperactivation was investigated in general for cancers harboring RTK dysregulation, or KRAS or BRAF mutations. 5 In HNSCC, ERK overexpression was observed in tumor cells as well as in infiltrating lymphoid cells. 5 ERK expression and activation was reported to be associated with clinicopathological parameters and cell proliferation in oral tongue squamous carcinoma. 5, 6 ERK inhibition could be an attractive strategy for anticancer therapies against thyroid cancer or advanced melanoma. Indeed, MEK and RAF inhibitors are compatible therapeutic agents for tumors addicted to ERK signaling. However, acquired resistance to these inhibitors and other targeted therapeutics can emerge in tumor cells. Several groups have investigated the mechanism of intrinsic (that is, present before treatment) or acquired resistance (acquired during treatment by various therapy-induced adaptive responses) against ERK blockades in many cancers. Selumetinib (AZD6244), a MEK1/2 inhibitor, provoked intrinsic resistance by PI3K signaling in colorectal cancer cells with KRAS or BRAF mutations. 7, 8 Some studies have generated evidence that acquired resistance to MEK inhibition induces feedback activation of several RTK called "kinome reprogramming" through the inhibition of a physiological negative loop. 9, 10 Currently, adaptive resistance to MEK inhibition is thought to be driven by feedback activation of fibroblast growth factor receptor 1 (FGFR1) among the RTK in KRAS-mutant lung cancer. 11, 12 However, the mechanism associated with acquired resistance to MEK inhibition has not been clearly determined.
Data from numerous studies have shown that ERK activation was intimately associated with acquired-resistance mechanisms. ERKactivity rebound appeared at an early phase after treatment with the RAF inhibitor vemurafenib in BRAF-mutant thyroid cancer cell lines resistant to vemurafenib, and this resistance was overcome using combination treatment with the HER kinase inhibitor lapatinib. 13 Rapid recovery of ERK signaling has also been shown in melanoma 
| MATERIAL S AND ME THODS

| Ethics statement
All animal experiment protocols were approved by the committee of ethics on animal research of Yonsei University College of Medicine (Accession No. 2014-0366). All mice were treated in accordance with the guidelines for the care and use of laboratory animals of the institutional animal care and use committee at our institute. 
| Cell lines and reagents
| Clonogenic assay
Cells were seeded at 2-5 × 10 4 cells/well in six-well plates and exposed to the indicated drugs for 24 hours. The culture medium was replaced every 3 days. After 14-21 days, the cells were fixed in 4% paraformaldehyde (PFA) and stained with 0.1% crystal violet.
Colonies containing at least 50 individual cells were counted using a stereomicroscope. 
| Immunoblotting
| Cell viability assay
Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Rockville, MD, USA) was used to determine cell viabilities, according to the manufacturer's instructions. Cells were plated in a 96-well plate at a density of 10 4 cells/well. After serum starvation, cells were treated with the indicated drugs for the indicated times or concentrations before adding CCK-8 solution (a water-soluble tetrazolium salt).
Cells were incubated for 1-2 hours, and the absorbance at 450 nm was measured using a microplate reader (Molecular Devices, San
Jose, CA, USA).
| Silencing of FGFR3 and FGF2
Cells were transfected with 100 nmol/L FGFR3 siRNA and 50 nmol/L FGF2 siRNA or a control siRNA (Santa Cruz Biotechnology, Dallas, TX, USA) using Lipofectamine RNAiMAX (Invitrogen) and incubated for 24 hours at 37°C in a humidified 5% CO 2 incubator. FGFR3
siRNA and FGF2 siRNA were designed and synthesized by Bioneer (Deajeon, Korea; sequences of FGFR3 siRNA and FGF2 siRNA can be seen in Table S1 , Data S1).
| Enzyme-linked immunosorbent assay
Cells were collected for the measurement of FGF2 concentration by FGF2 ELISA kit (Catalog no. ab99979, Abcam, Cambridge, UK).
Assays were carried out according to the manufacturer's instructions in a 96-well plate.
| Cell cycle analysis
Cell cycle progression was analyzed by propidium iodide (PI; Sigma) staining and flow cytometry. After drug treatment, the cells were trypsinized and washed in ice-cold PBS. After fixation in 70% ethanol, the cells were suspended in PI solution (50 μg/mL) containing DNase-free RNase (1 μg/mL) and incubated for 30 minutes at 37°C.
Measurement of the cellular DNA content was carried out using a BD
FACSVerse flow cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA) and analyzed using FlowJo v10 software (FlowJo, Ashland, OR). The mice were weighed once a week, and tumor growth was measured weekly using a digimatic caliper (Mitutoyo Co., Kawasaki-shi, Japan).
| Apoptosis assay
| Orthotopic xenograft mouse model
The mice were killed 52 days post-injection, and tumors were harvested to carry out histopathology and biochemical assays. Samples were fixed overnight in neutral buffered formalin, and immunohistochemical staining was carried out using tumor tissues and primary antibodies against Ki67, p-FGFR3, p-Akt, p-ERK, and cleaved caspase F I G U R E 1 MEK inhibitor induced an ERK-activity rebound and fibroblast growth factor receptor 3 (FGFR3) activation. A, Phosphorylated ERK and total ERK protein expression are shown in a representative western blot. Head and neck squamous cell carcinoma (HNSCC) cell lines were treated with 0.5 μmol/L AZD6244 or 0.1% DMSO as a vehicle control for different durations. AZD6244 was replaced with fresh media at the indicated times. GAPDH was detected as a loading control. B, Phospho-RTK assay in Cal27 cells treated with AZD6244 for 6 h. Cal27 cells incubated with 0.1% DMSO for 6 h served as a control. C, Representative western blot analysis of FGFR3, Akt, and ERK expression in Cal27 cells after treatment with 0.5 μmol/L AZD6244 for different time periods. Media containing AZD6244 was replaced with fresh media (lacking AZD6244) at the indicated times. GAPDH was detected as a loading control. D, Cell growth was measured in Cal27 cells treated with AZD6244 or PD173074 as an FGFR inhibitor in cell-viability assays. Cells were treated for 48 h with 0.1% DMSO, 0.5 μmol/L AZD6244 alone, 1 μmol/L PD173074, or 0.5 μmol/L AZD6244 with 1 μmol/L PD173074. Bars represent means ± SEM between replicates (n = 3). Significant differences compared to the corresponding controls, *P < .05. E, Clone-formation ability of Cal27 cells treated with AZD6244 was evaluated in clonogenic assays. Cal27 cells were treated with a dose gradient of AZD6244 in the absence or presence of 1 μmol/L PD173074 for 14 d and were studied in clonogenic assays. Bars represent means ± SEM between replicates (n = 3). Significant differences compared to the corresponding controls, **P < .01
3. Immunostained sections were analyzed by Allred score under a Nikon light microscope (Nikon, Tokyo, Japan) (Data S1). 17 Microscopy images were captured using AxioCam digital microscope cameras and AxioVision image processing (Carl Zeiss Vision).
| In vivo fluorescence imaging
Mice were injected with MMPsense 680 (PerkinElmer, Waltham, MA, USA) by tail vein injection. At 24 hours post-injection, the mice were imaged using an IVIS Spectrum instrument (Caliper LifeSciences, Waltham, MA, USA) while under anesthesia using isoflurane in oxygen.
Fluorescence images were recorded with a 1-second exposure using a 700/10 nm filter after excitation at 680 nm. Autofluorescence was removed using IVIS Spectrum Living Imaging Software.
| Statistical analysis
All data are represented as mean ± SD from three experiments carried out in triplicate. Comparative statistical analyses were done with Student's t test and one-way analysis of variance using SPSS 20.0 statistical software (SPSS, Chicago, IL, USA). P-values <0.05 were considered statistically significant (*P < .05; **P < .01; ***P < .001).
F I G U R E 2 Knockdown of fibroblast growth factor receptor 3 (FGFR3) abrogated ERK rebound and cell growth in head and neck squamous cell carcinoma (HNSCC) cells treated with AZD6244. A, Relative FGFR3, Akt, and ERK expression levels in Cal27 cells transfected with siFGFR3 or a scrambled oligo control (siControl) for 48 h, and treated with AZD6244 are shown by representative western blot analysis. HNSCC cell lines were treated with 0.5 μmol/L AZD6244 or 0.1% DMSO for different time periods. Media containing AZD6244 was replaced with fresh media (lacking AZD6244) at the indicated times. GAPDH was detected as a loading control. B, IC 50 of AZD6244 in HNSCC cell lines. Concentrations of AZD6244 (μmol/L) that inhibited the viability of Cal27, HN6, and FADU cells by 50% (IC 50 ) after 72 h were determined by MTT assays. Each value represents mean ± SEM from three independent experiments, carried out in triplicate. C, Cell growth was measured by cell viability assays with Cal27 cells treated as described in (A). Bars represent means ± SEM between replicates (n = 3). Significant differences compared to the corresponding controls, *P < .05. D, FGF2 expression in Cal27 cells treated with AZD6244 was determined using an FGF2 ELISA kit, as described in Materials and Methods. Cal27 cells were treated with AZD6244 for the indicated times. Bars represent means ± SEM between replicates (n = 3). Significant difference compared to the control, *P < .05. E, FGFR3, Akt, and ERK expression in Cal27 cells transfected with siFGF2 or siControl for 48 h, and treated with AZD6244 at the indicated times are shown with a representative western blot
| RE SULTS
| Extracellular signal-regulated kinase reactivation in MEK inhibitor-treated HNSCC cells
Recent reports have indicated that ERK activation is frequently dysregulated in cancer cells and is associated with anticancer-drug resistance. Therefore, we investigated whether the ERK pathway is related to resistance in HNSCC using AZD6244 as a selective MEK inhibitor to inhibit the ERK pathway. We used three cell lines: Cal27 cells and HN6 cells (established from human tongue carcinomas) and FADU cells (established from a human hypopharyngeal carcinoma).
The cells were treated with AZD6244 for the indicated durations, after which the medium was replaced with fresh medium lacking AZD6244 ( Figure 1A) . Results showed that ERK activation re- clearly reduced the number of colonies more so than did AZD6244 treatment alone ( Figure 1E ). These results showed that coinhibition of MEK and FGFR3 may synergistically increase the sensitivity of HNSCC cells to AZD6244.
| MEK inhibition upregulated FGFR3
To further investigate whether FGFR3 activation is effective against the AZD6244-induced ERK-activity rebound, siRNA against FGFR3 was used in Cal27 cells. We showed that the ERK-activity rebound arose under MEK inhibition and that the p-FGFR3 level increased gradually in Cal27 cells. When FGFR3 expression weakened, the ERK-activity rebound began to diminish at 6 hours post-AZD6244 treatment in Cal27 cells (Figure 2A , results of HN6 cells can be seen in Figure S2 ). As a result of the AZD6244 half-maximal in- 1.16 μmol/L), but these differences were not significant ( Figure 2B ).
After siFGFR3 transfection, proliferation of Cal27 cells was significantly reduced compared to that of control transfectants treated with scrambled siRNA ( Figure 2C ). Next, we explored FGF2 expression under MEK inhibition to determine the role of FGF2 in FGFR3
activation. FGF2, referred to as basic FGF, is a major ligand of FGFR3. In Cal27 cells, FGF2 level in the media increased time-dependently after treatment with AZD6244 ( Figure 2D ). In FGF2 siRNA transfectants, the p-FGFR3 level decreased and the ERK rebound also reduced, suggesting that FGF2 mediated FGFR3 feedback activation during MEK inhibition ( Figure 2E ). To rule out the off-target effects, two different siFGFR3 and siFGF2 were transfected to Cal27 cells as shown in Figure S3 and the representative result is shown in Figure 2 .
| Fibroblast growth factor receptor 3 inhibition and MEK inhibition induced apoptotic cell death
To explore the mechanism by which FGFR3 inhibition retarded cell proliferation, we analyzed cell cycle progression in Cal27 cells by flow cytometry. Sub-G1 distribution following combination treatment with AZD6244 and PD173074 increased, which represented delayed cell proliferation due to apoptotic cell death ( Figure 3A, histogram can be seen in Figure S4 ). Next, we used the selective Figure 3D ).
| Combination of FGFR inhibitor and MEK inhibitor leads to antitumor activity in vivo
We observed synergistic effects following combination treatment with the MEK inhibitor and FGFR inhibitor in vitro. To test whether FGFR inhibition could be an effective strategy for controlling resistance to MEK inhibition in vivo, we used an orthotopic xenograft mouse model of HNSCC. Cal27 cells were injected into the tongue of nude mice and tumor volume was evaluated on day 14. Mice were i.p. injected with vehicle, AZD6244, or both inhibitors in combination twice weekly (n = 4 mice/group). In Figure 4B , the presence of invasive orthotopic tumor was confirmed by an in vivo imaging system.
Tumor volumes were monitored on the indicated days. As shown in Figure 4A ,C, relative tumor volumes in the combination group were lower than those in the vehicle group or in the AZD6244 group.
AZD6244 treatment alone did not show a significant effect on tumor growth, whereas cotreatment with AZD6244 and PD173074 led to tumor regression. H&E staining showed that vehicle and AZD6244-treated tumors showed significantly greater tumor cellularities and sizes versus mice given combination treatment ( Figure 4D ). The molecular events were explored by immunohistochemical analysis.
Enhanced levels of Ki67 and p-FGFR3 were found in tumors of the vehicle-control and AZD6244 groups, indicating strong cell proliferation in the tumor masses ( Figure 4E , magnified images and Allred scores can be seen in Figure S6 and Table S2 ). In contrast, combination treatment with AZD6244 and PD173074 resulted in a significant decline in the levels of Ki67 and p-FGFR3, which was the result of inhibited tumor cell proliferation. Prevalence of apoptotic 
| D ISCUSS I ON
Targeted single-agent therapies that block highly oncogenic functions have a major limitation in that acquired resistance involves high levels of feedback activation of the related signaling network. The relative insensitivity of BRAF V600E-mutated melanoma to BRAF inhibition emerges through an enhanced level of cyclin D1. 18 Cyclin E overexpression confers insensitivity of trastuzumab in Her2+ breast cancer cells. 19 The lack of responsiveness of BRAF 26 FGF-FGFR autocrine loop signaling was induced after chronic adaptation to gefitinib and, thus, FGFR1-specific tyrosine kinase inhibitor (TKI) prevented acquired resistance to gefitinib. 27 We also showed that induction of the FGF2 ligand and FGFR3 following MEK inhibition promotes ERK reactivation and insensitivity to MEK inhibition. These findings provide evidence that FGFR signaling could serve as an additional candidate for a bypass mechanism in cancer cell lines rendered resistant to anticancer drugs. 
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